Cellular and molecular pathophysiology of cutaneous drug reactions

American Journal of Clinical Dermatology

Volumn 3, Issue 4, 2002, Pages 229-238

  Pichler, W J ^a   Yawalkar, N ^b   Britschgi, M ^a   Depta, J ^a   Strasser, I ^a   Schmid, S ^a   Kuechler, P ^a   Naisbitt, D ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Harvard Skin Disease Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CEFAZOLIN; CEFTRIAXONE; CELECOXIB; CYTOKINE; EOTAXIN; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN E; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METOLAZONE; PENICILLIN DERIVATIVE; PERFORIN; RANTES; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BULLOUS SKIN DISEASE; COVALENT BOND; CYTOTOXIC T LYMPHOCYTE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; EOSINOPHILIA; EXOCYTOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR BIOLOGY; PAPULAR SKIN DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUSTULE; RASH; REVIEW; SKIN MANIFESTATION;

EID: 0036281083     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203040-00001     Document Type: Review

References (66)

1. Comprehensive hospital drug monitoring (CHDM): Adverse skin reactions, a 20-year survey
2. Role of T cells in drug allergies
3. Lymphocyte activation in cutaneous drug reactions
4. T cell involvement in cutaneous drug eruptions
5. T cell involvement in drug-induced acute generalized exanthematous pustulosis
6. Characterization of lidocaine-specific T cells
7. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human T cell clones
8. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αaβb T lymphocytes
9. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction
10. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions
11. T cell immune response to haptens: Structural models for allergic and autoimmune reactions
12. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction
13. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes
14. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: Implications for allergies, asthma and autoimmunity
15. Studies on the sensitization of animals with simple chemical compounds
16. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective
17. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy
18. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals
19. Allergic and autoimmune reactions to xenobiotics: How do they arise?
20. Antigenicity and immunogenicity of sulfamethoxazole: Demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo
21. Metabolites and allergic drug reactions
22. A new chemical spectrum of penicillin allergy: The direct reaction of penicillin with epsilon-amino-groups
23. Sulfamethoxazole is metabolized to the hydroxylamine in humans
24. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions
25. Interaction of sulfonamide-derivatives with the TCR of sulfamethoxazole specific αβ+ T cell clones
26. HLA-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T cell clones
27. Recognition of sulfamethoxazole and its reactive metabolites by drug specific T cells from allergic individuals
28. Molecular basis of drug recognition by specific T cell receptors
29. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells
30. Predictive drug allergy testing, an alternative viewpoint
31. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection
32. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome
33. Adverse drug reactions in Sjögren syndrome: Frequent allergic reactions and a specific trimethoprim-associated systemic reaction
34. Danger signals: SOS to the immune system
35. Recent advances in the pathology of cutaneous drug eruptions
36. Morbilliform eruptions caused by penicillin: A study by electron microscopy and immunologic tests
37. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions
38. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection
39. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics
40. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes
41. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non immediate cutaneous allergic drug reactions
42. Perforin: More than just an effector molecule
43. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic
44. Up-regulated perforin expression of CD8+ blood lymphocytes in generalized non-anaphylactic drug eruptions and exacerbated psoriasis
45. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
46. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions
47. Distinct serum cytokine levels in drug or measles induced exanthema
48. Increased levels of Interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome
49. Immunohistochemical study of graft-versus-host reaction (GVHR)-type drug eruptions
50. Functional expression of the eotaxin receptor, CCR3, in T lymphocytes co-localizing with eosinophils
51. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?
52. Efficacy and safety of desensitization to allopurinol following cutaneous reactions
53. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors
54. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis
55. Significance of Fas antigen mediated apoptosis in human hepatic failure
56. Fatal liver necrosis due to allopurinol
57. Are intravenous immunoglobulins the treatment of Stevens-Johnson syndrome or toxic epidermal necrolysis?
58. Acute generalized exanthematous pustulosis: Analysis of 63 cases
59. Patch-testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
60. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management
61. Activation of drug specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine
62. Characterization of drug-specific T cells
63. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms
64. HHV-6 associated drug eruptions (HADE)
65. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia
66. Drug allergy: Relationship between immunogenicity and clinical symptoms